Covered recipient · General Payments record
AGNES OBITA-OUNDA
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$555.35
- Reported across 22 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $197.57 | 8 |
| Education | $19.01 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $69.51 | 2 |
| Novo Nordisk AS | $46.44 | 2 |
| Fresenius USA Marketing, Inc. | $23.69 | 1 |
| Ardelyx, Inc. | $22.45 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.33 | 1 |
| OPKO Pharmaceuticals, LLC | $19.01 | 1 |
| GlaxoSmithKline, LLC. | $15.15 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $39.71 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111667342 | CMS |
| Amgen Inc. | $29.80 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117344890 | CMS |
| Ardelyx, Inc. | $22.45 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146698400 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.33 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118091694 | CMS |
| Fresenius USA Marketing, Inc. | $23.69 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154200830 | CMS |
| GlaxoSmithKline, LLC. | $15.15 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116669046 | CMS |
| Novo Nordisk Inc | $22.01 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097805393 | CMS |
| Novo Nordisk Inc | $24.43 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097593630 | CMS |
| OPKO Pharmaceuticals, LLC | $19.01 | 03/04/2024 | Education | Undisputed | 01/23/2026 | 1112847924 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.